MX2018005588A - Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno. - Google Patents
Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno.Info
- Publication number
- MX2018005588A MX2018005588A MX2018005588A MX2018005588A MX2018005588A MX 2018005588 A MX2018005588 A MX 2018005588A MX 2018005588 A MX2018005588 A MX 2018005588A MX 2018005588 A MX2018005588 A MX 2018005588A MX 2018005588 A MX2018005588 A MX 2018005588A
- Authority
- MX
- Mexico
- Prior art keywords
- plasminogen
- deficiency
- subject
- replacement therapy
- deficient subject
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title abstract 11
- 108010051456 Plasminogen Proteins 0.000 title abstract 11
- 238000009256 replacement therapy Methods 0.000 title 1
- 230000002950 deficient Effects 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000009469 supplementation Effects 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Los objetos de la invención son un método complementación de plasminógeno en un sujeto con deficiencia de plasminógeno, y un método para el tratamiento de la deficiencia de plasminógeno en un sujeto con deficiencia de plasminógeno. Estos métodos comprenden la administración al sujeto con deficiencia de plasminógeno una dosis de plasminógeno, y, más particularmente, Glu-plasminógeno, para aumentar el nivel de la actividad de plasminógeno del sujeto en al menos aproximadamente 1% y, más particularmente en al menos aproximadamente 10%, de la actividad normal del plasminógeno y para mantener dicho aumento del nivel aumentado de actividad de plasminógeno durante un periodo de complementación o un periodo de tratamiento. El sujeto con deficiencia de plasminógeno de la presente invención puede sufrir deficiencia de plasminógeno tipo I, tipo II o una deficiencia de plasminógeno adquirida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250235P | 2015-11-03 | 2015-11-03 | |
| PCT/IB2016/001599 WO2017077380A1 (en) | 2015-11-03 | 2016-11-03 | Plasminogen replacement therapy for plasminogen-deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018005588A true MX2018005588A (es) | 2018-11-09 |
Family
ID=58661917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005588A MX2018005588A (es) | 2015-11-03 | 2016-11-03 | Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11291711B2 (es) |
| EP (1) | EP3370760B1 (es) |
| JP (1) | JP6878423B2 (es) |
| KR (1) | KR102821400B1 (es) |
| CN (1) | CN108289935A (es) |
| AU (1) | AU2016347863B2 (es) |
| BR (1) | BR112018008965A8 (es) |
| CA (1) | CA3002915C (es) |
| DK (1) | DK3370760T3 (es) |
| FI (1) | FI3370760T3 (es) |
| IL (1) | IL258913B (es) |
| LT (1) | LT3370760T (es) |
| MX (1) | MX2018005588A (es) |
| MY (1) | MY199581A (es) |
| PT (1) | PT3370760T (es) |
| RS (1) | RS67519B1 (es) |
| RU (1) | RU2736831C2 (es) |
| SM (1) | SMT202500451T1 (es) |
| TW (1) | TWI801331B (es) |
| WO (1) | WO2017077380A1 (es) |
| ZA (1) | ZA201802820B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201722464A (zh) * | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| WO2017101866A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| TWI653981B (zh) | 2015-12-18 | 2019-03-21 | 深圳瑞健生命科學硏究院有限公司 | Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury |
| JP6682008B2 (ja) | 2015-12-18 | 2020-04-15 | タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ | 糖尿病性腎症を予防及び治療するための方法 |
| US11338022B2 (en) | 2015-12-18 | 2022-05-24 | Talengen International Limited | Method for preventing and treating angiocardiopathy |
| EP3429636A4 (en) * | 2016-03-17 | 2019-11-20 | Vanderbilt University | IMPROVEMENT OF PLASMINACTIVITY FOR PREVENTING SOFT TISSUE CALIBRATION |
| US11389515B2 (en) | 2016-12-15 | 2022-07-19 | Talengen International Limited | Method for mitigating heart disease |
| EP3556395A4 (en) | 2016-12-15 | 2020-07-22 | Talengen International Limited | METHOD OF PREVENTION AND TREATMENT OF PULMONARY FIBROSIS |
| US11129880B2 (en) * | 2016-12-15 | 2021-09-28 | Talengen International Limited | Method for promoting insulin secretion |
| CA3047181A1 (en) | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method and drug for preventing and treating obesity |
| TW201822812A (zh) * | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | 一種預防和治療肥胖症的方法 |
| CN109125715A (zh) * | 2017-06-19 | 2019-01-04 | 深圳瑞健生命科学研究院有限公司 | 一种调控glp-1/glp-1r的方法和药物 |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CN113597313A (zh) * | 2019-01-24 | 2021-11-02 | 先觉药业咨询公司 | 用于治疗和预防微血栓形成的纤溶酶原 |
| EP3812772B1 (en) * | 2019-10-24 | 2025-02-19 | Hôpitaux Universitaires de Strasbourg (HUS) | Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps |
| WO2021214320A1 (en) | 2020-04-23 | 2021-10-28 | Previpharma Consulting Gmbh | Plasminogen for use in treating and preventing lung dysfunction |
| CN114354929A (zh) * | 2022-01-07 | 2022-04-15 | 南京鼓楼医院 | 一种用于监测人体纤溶状态的试剂盒及应用 |
| WO2025049724A1 (en) * | 2023-08-29 | 2025-03-06 | Board Of Regents Of The University Of Nebraska | Compositions and methods for treating pleural space infections and hemothorax |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2254316B1 (es) | 1973-12-18 | 1977-04-22 | Choay Sa | |
| JP2764264B2 (ja) * | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| AU4661493A (en) * | 1992-07-01 | 1994-01-31 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| WO1994018315A1 (en) * | 1993-02-05 | 1994-08-18 | Vascular Laboratories, Inc. | Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis |
| US20030224516A1 (en) * | 2002-06-03 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of prox-1 expression |
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US20050271636A1 (en) * | 2002-08-09 | 2005-12-08 | St. Jude Children's Research Hospital, Inc. | Diagnostic and therapeutic uses for prox 1 |
| GB0509438D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| ES2451015T3 (es) * | 2006-08-28 | 2014-03-26 | Omnio Healer Ab | Candidatos contra la infección |
| AU2007290882B2 (en) | 2006-08-28 | 2013-02-21 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| EP2451835A1 (en) * | 2009-07-10 | 2012-05-16 | ThromboGenics N.V. | Variants of plasminogen and plasmin |
| EP2611466B1 (en) * | 2010-08-30 | 2019-06-12 | President and Fellows of Harvard College | Shear controlled release of thrombolytic therapies for stenotic lesions |
| UA123496C2 (uk) * | 2014-12-19 | 2021-04-14 | Прометік Байо Терап'Ютікс, Інк. | Фармацевтична композиція, що містить плазміноген, та її застосування |
| CA3008691A1 (en) * | 2015-12-18 | 2017-06-22 | Talengen International Limited | Method for preventing or treating diabetic retinopathy |
-
2016
- 2016-11-02 TW TW105135535A patent/TWI801331B/zh active
- 2016-11-03 RS RS20251224A patent/RS67519B1/sr unknown
- 2016-11-03 SM SM20250451T patent/SMT202500451T1/it unknown
- 2016-11-03 DK DK16861682.9T patent/DK3370760T3/da active
- 2016-11-03 MX MX2018005588A patent/MX2018005588A/es unknown
- 2016-11-03 BR BR112018008965A patent/BR112018008965A8/pt not_active Application Discontinuation
- 2016-11-03 EP EP16861682.9A patent/EP3370760B1/en active Active
- 2016-11-03 CA CA3002915A patent/CA3002915C/en active Active
- 2016-11-03 CN CN201680067482.XA patent/CN108289935A/zh active Pending
- 2016-11-03 KR KR1020187015657A patent/KR102821400B1/ko active Active
- 2016-11-03 US US15/771,454 patent/US11291711B2/en active Active
- 2016-11-03 AU AU2016347863A patent/AU2016347863B2/en active Active
- 2016-11-03 MY MYPI2018000585A patent/MY199581A/en unknown
- 2016-11-03 PT PT168616829T patent/PT3370760T/pt unknown
- 2016-11-03 LT LTEPPCT/IB2016/001599T patent/LT3370760T/lt unknown
- 2016-11-03 JP JP2018522753A patent/JP6878423B2/ja active Active
- 2016-11-03 WO PCT/IB2016/001599 patent/WO2017077380A1/en not_active Ceased
- 2016-11-03 FI FIEP16861682.9T patent/FI3370760T3/fi active
- 2016-11-03 RU RU2018120182A patent/RU2736831C2/ru active
-
2018
- 2018-04-24 IL IL258913A patent/IL258913B/en unknown
- 2018-04-26 ZA ZA2018/02820A patent/ZA201802820B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201722463A (zh) | 2017-07-01 |
| DK3370760T3 (da) | 2025-12-22 |
| FI3370760T3 (fi) | 2025-12-05 |
| NZ742657A (en) | 2024-04-26 |
| AU2016347863B2 (en) | 2023-11-09 |
| MY199581A (en) | 2023-11-07 |
| IL258913B (en) | 2021-12-01 |
| CN108289935A (zh) | 2018-07-17 |
| BR112018008965A2 (pt) | 2018-11-21 |
| KR102821400B1 (ko) | 2025-06-18 |
| RS67519B1 (sr) | 2025-12-31 |
| AU2016347863A1 (en) | 2018-06-07 |
| EP3370760B1 (en) | 2025-10-01 |
| PT3370760T (pt) | 2025-12-03 |
| CA3002915A1 (en) | 2017-05-11 |
| JP2018533589A (ja) | 2018-11-15 |
| BR112018008965A8 (pt) | 2019-02-26 |
| WO2017077380A1 (en) | 2017-05-11 |
| RU2018120182A3 (es) | 2020-04-27 |
| IL258913A (en) | 2018-06-28 |
| EP3370760A4 (en) | 2019-06-26 |
| US20190231854A1 (en) | 2019-08-01 |
| EP3370760A1 (en) | 2018-09-12 |
| RU2018120182A (ru) | 2019-12-04 |
| RU2736831C2 (ru) | 2020-11-20 |
| US11291711B2 (en) | 2022-04-05 |
| JP6878423B2 (ja) | 2021-05-26 |
| SMT202500451T1 (it) | 2026-01-12 |
| LT3370760T (lt) | 2025-12-29 |
| TWI801331B (zh) | 2023-05-11 |
| KR20180083348A (ko) | 2018-07-20 |
| ZA201802820B (en) | 2019-07-31 |
| CA3002915C (en) | 2024-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018005588A (es) | Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno. | |
| MX2021009830A (es) | Metodos para el tratamiento de trastornos del movimiento involuntario anormal. | |
| MY187486A (en) | Cysteine protease | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| ZA201705113B (en) | Cysteine protease | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2022007989A (es) | Composiciones y metodos para tratar pterigion. | |
| GB2541571A (en) | Pharmaceutical compositions | |
| NZ750174A (en) | Somatostatin modulators and uses thereof | |
| MX2019010949A (es) | Moduladores de somatostatina y usos de los mismos. | |
| SG10201808063PA (en) | Compositions for modulating ataxin 2 expression | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| MX2017017171A (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| MX2020003243A (es) | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder | |
| TW201613639A (en) | Methods for treating cardiovascular diseases | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| EP3725320C0 (en) | COMPOSITION COMPRISING A STRAIN OF AGATHOBACULUM SP. AS AN ACTIVE INGREDIENT FOR THE PREVENTION, MITIGATION OR TREATMENT OF AN AUTISM SPECTRUM DISORDER | |
| PH12017501918A1 (en) | Multi-peptide composition | |
| WO2018089204A3 (en) | Combination therapies for treating bipolar disorder, and methods for using the same | |
| MX2017013669A (es) | Composiciones para el tramiento del cancer. | |
| UA98863U (en) | Method for treating endometrial hyperplasia of patients of reproductive age | |
| UA104615U (uk) | Спосіб лікування токсокарозу |